Altogether, while the above-reported pharmacokinetic and pharmacodynamic proprieties of KLS suggest potential for use in COVID-19 patients, at this time no significant evidence from studies in COVID-19 are currently available. The gene discussed is RPS6KB2; the disease is COVID-19.